Inventiva (IVA) S.A. is a clinical-stage biopharmaceutical company headquartered in Daix, France, with shares listed on both Euronext Paris and the Nasdaq Global Market under the ticker IVA. The company is focused on oral small-molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH), a common and progressive chronic liver disease formerly known as NASH.
Its lead candidate, lanifibranor, is a novel pan-PPAR agonist designed to activate all three PPAR isoforms (alpha, delta, and gamma) in a balanced, moderate manner. Lanifibranor has received both Breakthrough Therapy and Fast Track designations from the FDA. The drug is being evaluated in the NATiV3 pivotal Phase 3 trial, which enrolled 1,009 patients in its main cohort of biopsy-confirmed, non-cirrhotic MASH patients with F2 or F3 fibrosis, alongside an exploratory cohort. Investors follow IVA closely because the company is effectively a single-asset, binary bet on the outcome of that pivotal readout. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, IVA shares moved from a closing price of $3.55 to $3.14, a decline of approximately 11.5%. The downtrend was not linear: the stock traded near $3.83 in early November before fading through the month, reflecting heightened volatility ahead of a major data catalyst.
The quarterly picture is materially weaker. From roughly $4.68 in late August, the stock has fallen about 33% to $3.14. A sharp mid-September selloff, followed by a partial October recovery and renewed November weakness, left shares well below their earlier-summer levels. The overall pattern reflects a prolonged de-risking phase as investors await the NATiV3 top-line results.
The recent decline has been driven less by any single adverse announcement and more by positioning ahead of Inventiva's pivotal catalyst. The company presented multiple scientific abstracts at AASLD The Liver Meeting 2026 in early November, which underscored the science behind lanifibranor but delivered no pivotal efficacy data, leaving the binary Phase 3 outcome unresolved.
Investor caution has also been reinforced by the company's financing position. Inventiva reported a first-half 2026 net loss of roughly €69.5 million against €233.9 million in cash and short-term deposits as of June 30, 2026, with a runway extending only through the second quarter of 2027 and going-concern language in its regulatory filings. Broader pressure on clinical-stage biotech names and an increasingly competitive MASH field — including approved therapies from companies such as Madrigal Pharmaceuticals (MDGL) — have added to the negative sentiment.
The quarterly decline reflects a broader re-rating of Inventiva's risk profile. After a June 2026 refinancing that included committed debt financing of up to €130 million and a U.S. ADS offering, the stock steadied before a sharp September selloff pushed shares from above $4.60 toward the mid-$3 range.
Management's first-half 2026 results, reported in late September, reaffirmed the Q4 2026 timing for NATiV3 top-line data and a potential NDA submission in the first half of 2027, while also confirming the completion of the final patient's 72-week visit. However, the company's limited cash runway, ongoing need for additional capital, and the lingering overhang of dilution continued to cap upside. The stock's trajectory has also tracked the broader risk-off tone in the MASH and metabolic-disease biotech complex, where names such as Viking Therapeutics (VKTX) have faced similar pressure. From what I see, reviewing historical patterns with Tickeron’s AI Pattern Search Engine added useful context here.
The single most important upcoming catalyst is the NATiV3 Phase 3 top-line readout, expected in the fourth quarter of 2026. The trial's co-primary histology endpoints — MASH resolution without worsening of fibrosis, and fibrosis improvement without worsening of MASH — will determine whether lanifibranor can support a potential NDA submission in the first half of 2027.
Beyond efficacy, investors will scrutinize the safety and tolerability profile, particularly weight gain, edema, and hemoglobin changes, given their implications for commercial adoption. Financing remains a central risk: the company's cash position does not currently fund the next twelve months of operations, and future equity raises could dilute existing holders. Finally, the evolving competitive MASH landscape, including approved agents and GLP-1-based approaches, plus broader biotech sector sentiment, will continue to shape the stock's direction. I’m watching this closely as the data approaches.
In my research process, I often turn to Tickeron’s Trending AI Robots page. It highlights a curated selection of AI-driven trading bots from a platform that operates hundreds of bots across thousands of tickers. Only the top-performing and most relevant strategies are surfaced, allowing traders to review bots that vary by approach, timeframe, and performance metrics. Because each bot differs in its trading logic and risk profile, the page offers a useful starting point for investors evaluating automated strategies that might complement their own analysis of volatile names like IVA.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
IVA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 36 of 40 cases where IVA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 10-day moving average for IVA crossed bullishly above the 50-day moving average on November 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Following a +7.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where IVA advanced for three days, in 175 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 126 of 156 cases where IVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
The 10-day RSI Indicator for IVA moved out of overbought territory on November 04, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 20 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IVA as a result. In 87 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for IVA turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 34 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
IVA moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. IVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.215) is normal, around the industry mean (3.596). P/E Ratio (-7.170) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (136.986) is also within normal values, averaging (443.347).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IVA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company, which engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases
Industry Biotechnology